EULAR 2018 Review
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
In a separate dedicated Phase 1 study, Mohamed and colleagues examined the<br />
pharmacokinetics of upadacitinib in 18 volunteers with either normal renal function, or mild<br />
or moderate renal impairment. In participants with mild and moderate hepatic impairment,<br />
upadacitinib exposure ratio central values following a single 15 mg dose were 1.28, 1.24<br />
for AUC and 1.04, and 1.43 for maximum plasma concentration, relative to participants<br />
with normal renal function. The authors concluded that renal impairment has very limited<br />
effect upon upadacitinib pharmacokinetics (